Health
Ultrapotent compound may help treat C. diff, reduce recurrence – Medical Xpress
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.
Only two antibiotics, vancomycin and fidaxomicin, are FDA approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence.
Now, Purdue University innovators have advanced novel compounds they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Preventio…
-
Business23 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News22 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News23 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
General13 hours agoThe right-wing stupidity repeating Liberal Party history